v3.21.1
Condensed Balance Sheets - USD ($)
Mar. 31, 2021
Dec. 31, 2020
Current assets:    
Cash $ 9,609,631 $ 13,953,513
Grants receivable 332,774  
Prepaid research and development 712,674 774,356
Prepaid expenses and other current assets 1,216,173 54,837
Total 11,871,252 14,782,706
Deferred offering costs 2,783  
Total assets 11,874,035 14,782,706
Current liabilities:    
Accounts payable 715,016 1,720,680
Accrued expenses and other current liabilities 627,399 632,934
Deferred revenue 1,251,349 2,325,741
Notes payable 994,789 42,534
Total 3,588,553 4,721,889
Notes payable, net of current portion 248,911 276,461
Total liabilities 3,837,464 4,998,350
Commitments and contingencies (see Note 11)
Stockholders’ equity:    
Preferred stock, $0.001 par value; 10,000,000 shares authorized at March 31, 2021, and December 31, 2020; 0 shares issued and outstanding at March 31, 2021, and December 31, 2020
Common stock, $0.001 par value; 100,000,000 and 30,000,000 shares authorized; 10,059,849 and 10,050,849 shares issued and outstanding at March 31, 2021 and December 31, 2020, respectively. 10,060 10,051
Additional paid-in capital 25,695,203 24,805,929
Accumulated deficit (17,668,692) (15,031,624)
Total 8,036,571 9,784,356
Total liabilities and stockholders’ equity $ 11,874,035 $ 14,782,706

Source